As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter ...

Is BioMarin stock a bargain or a falling knife? Learn about key issues affecting its investment prospects and potential for recovery.

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

a less useful outcome-based KPI for pharma than for other industries." High performing sales organisations operationalise their call coverage models off a clearly defined plan that begins with ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its third-quarter 2024 earnings, highlighting a steady increase in revenue and strategic developments in product innovation and market expansion. Despite ...

NPPA calls for price data on diagnostic agent iohexol following DoP's review order: Gireesh Babu, New Delhi Thursday, January 23, 2025, 08:00 Hrs [IST] The National Pharmaceutical ...

This is particularly true when it comes to technology and the current systems that most pharmaceutical companies deploy. Traditional sales software has been essentially a call reporting and ...

Welcome to “Sector Spotlight,” where The Fly looks at a new industry every week and highlights its happenings. Stay Ahead of the ...

Big things are happening at Acadia Pharmaceuticals ... Medicines Agency, and sales in Europe could kick off as early as Q2 2025. CEO Catherine Owen Adams calls this a pivotal year for Acadia ...

The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a cautious approach to buying other companies, which are expensively priced."We ...